Where to Buy Semax Peptide Online in the USA: Benefits, Price, COA & Supplier Guide (2026)
Direct answer: When comparing where to buy Semax peptide online for U.S. laboratory research, verify the exact heptapeptide sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), the stated free-base or acetate form, vial strength, 10-vial package, lot-matched COA, and U.S. fulfillment record. These checks matter because “Semax” is also used for modified analogues and differently named forms.
Fact-checked by NEXTWAVE PEPTIDES Editorial Team

Strengths: 5 or 10 mg per vial · Package: 10 vials per box · Observed starting price: $59 on November 10, 2026.
Check the current Semax peptide research material page for available strength, stock, and the matching lot record.
What is Semax?
Unmodified Semax is commonly described as ACTH(4-7)-PGP and written as MEHFPGP. That seven-residue identity is not the same as N-acetyl Semax amidate or another terminally modified analogue. The Semax vs N-acetyl Semax amidate guide maps the terminal modifications, while the ACTH fragment comparison explains why Semax is a distinct peptide record rather than simply ACTH(4-10).
A human functional-connectivity study included 52 healthy participants and used resting-state fMRI before and after Semax, Selank, or placebo. The primary report measured network connectivity, not consumer cognitive performance, and its administration details and short observation window remain part of the result.
Supplier checklist for Semax research material
| Field | What to verify | Why it matters | Red flag |
|---|---|---|---|
| Identity | Full MEHFPGP sequence and form | Separates Semax from modified analogues | Only “nootropic peptide” |
| Strength | mg per vial and vials per box | Allows total labeled-amount comparison | Box price without vial basis |
| COA | Lot, identity method, purity method, content, date | Connects the report to the received lot | Generic certificate without lot |
| Fulfillment | Warehouse and current stock statement | Clarifies shipping record | Unverifiable location or changing seller name |
| Evidence | Exact model, route, endpoint, and source | Prevents evidence transfer between forms | Benefits list without source context |
FDA's 2026 Semax compounding review is especially relevant to identity. It notes inconsistent naming across salts and derivatives, no applicable USP/NF monograph, and no Semax component in an FDA-approved drug. The review addresses compounding policy and safety; it does not invalidate analytical laboratory research, but it raises the value of exact naming and traceable reference standards.
What does the research say about benefits?
Semax research spans neural signaling, gene-expression, ischemia models, and small human studies. The evidence is heterogeneous. A rat ischemia study of ACTH(4-7)-PGP measured changes in immune- and neurosignaling-related gene expression after transient middle cerebral artery occlusion. That transcriptomic experiment supports a mechanistic research question, while species, ischemia model, sampling time, and gene-expression endpoints limit transfer to humans.
The Semax transcriptome guide shows how to read fold changes and pathway enrichment without converting them into clinical outcomes. For comparison with another peptide often searched in neural research, the Semax vs Selank evidence map separates sequence, origin, study design, and endpoint.
How to compare price correctly
A $59 10-vial box of 5 mg vials represents 50 mg total labeled material. A $89 box of 10 mg vials represents 100 mg total labeled material. The lower box price and the lower price per labeled milligram are therefore not automatically the same choice. Compare total labeled amount, required analytical documentation, stock, and shipping record. Current neural and laboratory materials are grouped in the Research Compounds collection.
Before ordering, open the COA library and match product, strength, and lot. An HPLC area percentage describes chromatographic composition under one method; an identity result such as mass spectrometry answers a different question. Both should be linked to the same sample.
Semax versus Selank: related searches, different peptide records
Semax and Selank are often grouped as neural-research peptides, but their sequences and development histories differ. Semax is the seven-residue MEHFPGP peptide. Selank is a tuftsin-derived heptapeptide with a separate sequence, target literature, and analytical mass.
The human fMRI study cited above included both compounds, which makes it useful for within-protocol comparison. It still does not make the molecules substitutes. Each arm used a defined material, and the connectivity endpoints do not establish equal effects in other assays.
Researchers evaluating both can compare the separate Selank peptide listing and maintain two evidence worksheets. A shared “neural peptide” label should never replace compound-specific sequence, form, content, and lot records.
How to read a Semax COA without overvaluing one number
A high HPLC area percentage is useful, but it represents the proportion of detected chromatographic peaks under specified conditions. It does not independently confirm the primary peak is Semax, determine the exact amount in the vial, or identify every impurity.
Mass spectrometry can support molecular identity by comparing observed and expected mass. Quantitative content requires its own calibrated method or stated basis. Water, counterions, residual solvents, and other non-peptide components may also affect net content without appearing as peptide-related HPLC peaks.
For practical review, place identity, chromatographic purity, content, lot number, sample name, test date, and laboratory information in separate fields. If a report omits one field, record it as missing rather than treating another field as a substitute.
Shipping, receipt, and record retention
Supplier verification continues after checkout. On receipt, photograph the intact package and labels, record the delivery date and condition, and compare the received strength and lot with the invoice and COA. Save the original files rather than relying on a page that may later change.
For multi-month projects, retain a lot-specific storage and aliquot log. This creates a reproducible chain from online listing to received material, analytical record, storage history, and experiment date.
Original analysis: separate name risk from evidence risk
Semax procurement has two independent risks. Name risk occurs when “Semax” hides a salt or modified analogue. Evidence risk occurs when a result from one route, model, or endpoint is applied to a different material. A strong supplier record reduces name risk; careful source reading reduces evidence risk. Neither one substitutes for the other.
A practical worksheet should therefore have separate columns for supplier-stated identity, analytical identity, source-study identity, and any difference between them. Add sequence, terminal modifications, counterion, expected mass, lot, and report date. This layout makes disagreements visible before material is introduced into a protocol.
Researchers can also record storage condition, sample handling, and the date the report was downloaded so later protocol reviews preserve the original purchasing context.
Research limitations
Semax does not have a U.S. FDA-approved drug-product record, and much of the literature uses animal models, region-specific clinical records, or short-window biomarkers. Online prices and stock change. A research COA supports lot traceability, not therapeutic effectiveness or dosing.
Frequently asked questions
What sequence should standard Semax show?
Unmodified Semax is commonly recorded as MEHFPGP, or ACTH(4-7)-PGP.
Is Semax acetate the same record as Semax free base?
No. The active sequence may be related, but salt or counterion form should remain explicit in identity and mass records.
What is a useful Semax COA?
It matches the product lot and reports identity, expected and observed mass, content basis, purity method, date, and sample traceability.
Does a human fMRI study prove broad cognitive benefits?
It establishes measured connectivity findings under that protocol. Broader outcomes require trials designed for those endpoints.